7. (Amended) The method of claim 6, wherein the [agent] non-binding FK506 analog is selected irrespective of its ability to inhibit FKBP-12 rotamase activity.

11. (Amended) The method of claim 6 wherein selecting a FK506 analog that does not bind FKBP-12 comprises selecting a FK506 analog that does not [substantially] inhibit FKBP-12 rotamase activity in a statistically significant manner. → no support on page 17 11 2nd

the scope of the claim has been changed

12. (Amended) [A method of identifying a non-binding FK506 analog that stimulates nerve cell growth the method comprising]], The method of claim 6, further comprising:

screening [a ~~plurality of~~] the FK506 [analogs for binding to FKBP-12 and] analog that does not bind FKBP-12 and for rotamase inhibition activity;

selecting a FK506 analog [of interest] that does not bind FKBP-12 [and which has] for low rotamase inhibition; and

new step

assaying the FK506 analog that does not bind FKBP-12 and has low rotamase inhibition [of interest] for activity in promoting cell growth.

14. (Amended) [A method of identifying a FK506 analog that stimulates nerve cell growth, the method comprising:] The method of claim 6, wherein

[screening FK506 analogs for binding to FKBP-12; → new limitation

selecting one or more] the non-binding FK506 [analogs of interest] analog that stimulates nerve cell growth [that bind] binds FKBP-12 with a K_d of at least 10 μM[; and

performing additional assaying of one or more of the analogs of interest for activity in promoting nerve cell growth].

15. (Amended) The method of claim [14] 6, [wherein the additional assaying] wherein the assay for activity in promoting nerve cell growth comprises exposing a cell to the [analog of interest] non-binding FK506 analog and determining if neurite outgrowth is promoted.